Introduction {#s0005}
============

Over the past decades, the incidence and mortality rate of gastric cancer (GC) have been steadily decreased. However, GC is still one of the most common malignancies nowadays, with a high incidence of recurrence and metastasis even after curative resection [@bb0005], [@bb0010]. In China, GC is the second leading cause of cancer death among both men and women in 2015 [@bb0015]. Despite advances in surgical techniques, the long-term postoperative survival of GC patients is still poor with the relatively late stage of diagnosis [@bb0020].

In many cancers, independent prognostic factors are useful for selecting high-risk patients and tailoring treatment. Currently, pathologic stage and lymph nodes status, which determine the GC American Joint Committee on Cancer stages, represent the gold standard for assessing GC prognosis after radical surgery [@bb0025]. However, many other tumor features have also been validated to play an important role in predicting the postoperative survival in GC. For example, systemic inflammatory response has been consistently recognized to confer poorer outcome in patients with various cancers and become the hot topic for clinicians and researchers [@bb0030], [@bb0035], [@bb0040]. Moreover, cancer-associated malnutrition is also increasingly appreciated to have a major role [@bb0045], [@bb0050]. Malnutrition, defined as a nutritional status in which there is a deficiency of energy, protein, and other nutrients, can negatively influence the defensive system in our body and may cause adverse clinical outcomes [@bb0055], [@bb0060]. However, up to now, no ideal indices exist to evaluate patients for preoperative nutritional risk [@bb0065]. In recent years, nutritional deficiency (ND), a nutritional-based index, has been demonstrated as a strong predictor of postoperative outcomes in urologic malignancies [@bb0070], [@bb0075]. With regard to GC, the clinical significance and prognostic value of this index remain uncertain.

In the present study, we aimed to investigate the prognostic utility of preoperative ND, as measured by body mass index (BMI), serum albumin, and preoperative weight loss, in patients undergoing curative resection for GC.

Material and Methods {#s0010}
====================

Ethics Statement {#s0015}
----------------

The study complied with the standards of the Declaration of Helsinki and was approved by the Research Ethics Committee at the Cancer Center of Sun Yat-sen University. Written informed consent was obtained from each patient.

Study Population {#s0020}
----------------

This study reviewed 1026 patients undergoing curative resection for GC at Cancer Center of Sun Yat-sen University between January 2003 and December 2012. All patients were histologically confirmed as having stage I to III gastric adenocarcinoma, with stage determined according to the 7th edition of the American Joint Committee on Cancer tumor-nodes-metastasis (TNM) classification [@bb0025]. According to current guidelines, patients with stage II or stage III GC and no significant comorbidities precluding chemotherapy use were offered primarily 5-fluorouracil--based adjuvant chemotherapy after surgery [@bb0080], [@bb0085], [@bb0090]. The exclusion criteria were as follows: 1) no entire set of clinicopathological and laboratory data, 2) neoadjuvant chemotherapy or radiotherapy, 3) preoperative nutritional intervention (e.g., albumin) within 1 month before surgery, and 4) clinical evidence of non--cancer-related malnutrition.

Data Acquisition {#s0025}
----------------

Clinicopathological and outcome data were collected by review of the medical records. Routine laboratory measurements, including the serum levels of carcinoembryonic antigen (CEA) and albumin, were carried out within 1 week before surgery. Unintentional preoperative weight loss within 6 months was recorded at the time of diagnosis. Regarding the histological grade, patients with papillary and well- or moderately differentiated GC were categorized as the well-differentiated histology group, and those with undifferentiated, signet ring cell, and mucinous GC were categorized as the poorly differentiated histology group [@bb0095].

Nutritional-Based Indices {#s0030}
-------------------------

The BMI was calculated as previously described (\<18.5 kg/m^2^, ≥18.5 to \<25.0 kg/m^2^, ≥25.0 kg/m^2^) [@bb0100]. Based on previous studies, preoperative weight loss was divided into three groups: \<5% weight loss, 5% to 10% weight loss and \>10% weight loss [@bb0075].

Patients were categorized into two groups: nutritionally replete (NR) and ND. ND was defined as meeting one or more of the following criteria: BMI \<18.5 kg/m^2^, preoperative albumin \<35 g/l, or preoperative weight loss ≥5% of body weight [@bb0070], [@bb0075].

Follow-Up {#s0035}
---------

Patients were routinely followed up every 3 months during the first 2 years and every 6 months thereafter, including the laboratory testing, dynamic abdominal computed tomography, and gastroscope examination. The latest follow-up was June, 2015. Overall survival (OS) was defined as the duration from the date of surgery until death or last follow-up.

Statistical Analysis {#s0040}
--------------------

Comparisons between groups were performed using the *χ*^2^ test for categorical variables. Cumulative survival was estimated using the Kaplan-Meier method, and differences in survival rates between the groups were assessed by the log-rank test. Variables that proved to be significant (*P* \< .05) in the univariate analysis and not significantly associated with others were subsequently entered into a multivariate Cox proportional hazards model. All statistical analyses were performed using the SPSS statistical software package, version 19.0 (IBM Corporation, Armonk, NY). A two-sided *P* value \< .05 was considered significant.

Results {#s0045}
=======

A total of 1026 GC patients were enrolled; 700 (68.2%) patients were males, and 326 (31.8%) were females. The median age was 59 years, with an age range from 19 to 89 years. A total of 177 patients were in stage I, 257 were in stage II, and 592 were in stage III ([Table 1](#t0005){ref-type="table"}). Overall, 585 (57.0%) met the criteria for ND with one or more of the following: BMI \<18.5 kg/m^2^ (39.1%), preoperative albumin \<35 g/l (8.3%), and preoperative weight loss ≥5% (32.4%). One hundred seventy patients (16.6%) had 2 ND factors, and 28 patients (2.7%) had 3. The median follow-up period was 34 months (range 1-136). During the follow-up period, 397 (38.7%) patients died, and 629 (61.3%) were alive at last follow-up.

OS at 5 years was 68.5% for ND patients and 44.0% for NR patients (*P* \< .001). The NR patients (96.8 months) had significantly longer mean survival compared with ND patients (68.8 months) (*P* \< .001). The results of the univariate analysis were shown in [Table 2](#t0010){ref-type="table"}. Because of correlations among the BMI, serum albumin, preoperative weight loss, and nutrition status, the variables (age, tumor size, tumor location, histological grade, anemia, nutrition status, CEA, and TNM stage) were tested in a multivariate analysis. Multivariate analysis revealed that ND was a strong predictor of OS (hazard ratio \[HR\]: 1.954; 95% confidence interval (CI): 1.552-2.460; *P* \< .001; [Table 2](#t0010){ref-type="table"}). In stage-stratified analysis, it was still independently associated with OS in TNM stage II and III (*P* = .004 and *P* \< .001, respectively). However, its prognostic value was limited in TNM stage I (*P* = .146; [Figure 1](#f0005){ref-type="fig"}). Furthermore, the prognostic significance of ND was still maintained when stratified by age, sex, anemia, and adjuvant chemotherapy (all *P*s \< .05; [Figures 2](#f0010){ref-type="fig"} and [3](#f0015){ref-type="fig"}). It should be noted that ND was still associated with OS in patients with BMI ≥18.5 kg/m^2^, preoperative weight loss \<5% of body weight, or serum albumin ≥35 g/l, respectively (all *P*s \< .001; [Figure 4](#f0020){ref-type="fig"}).

The relationship between nutrition status and clinicopathologic characteristics in GC patients was shown in [Table 3](#t0015){ref-type="table"}. Our study showed that ND was associated with age ≥ 60 years (*P* = .030), female patients (*P* \< .001), larger tumor size (*P* \< .001), higher TNM stage (*P* \< .001), the presence of preoperative anemia (*P* \< .001), and elevated CEA (*P* = .006).

Discussion {#s0050}
==========

Because of the adverse impact on physical, psychological, and social functions caused by cancer, malnutrition is common in patients with cancer, especially gastrointestinal malignancies [@bb0105], [@bb0110]. Estimated prevalence rates can range from 9% in urological cancer and up to 85% in pancreatic cancer [@bb0115]. Accumulating evidence has indicated that malnutrition is associated with a series of clinical consequences, including poor quality of life, decreased response to adjuvant treatment, increased risk of chemotherapy-induced toxicity, and poor outcome [@bb0120], [@bb0125]. Therefore, early identification of malnutrition is of vital importance among cancer patients, especially considering that effective nutritional intervention may have an important role in reducing postsurgical morbidity and mortality.

Over the past decades, a number of nutritional-based scores have been proposed for determining the prognostic impact of nutritional status in patients with various cancers. Recently, a prospective study from Minami al, which used pretreatment BMI to evaluate nutritional status, revealed that nutritional status might be a valuable prognostic indicator in older GC patients [@bb0130]. A study from our center provided concrete evidence that critical weight loss was a significant and independent predictor of long-term survival in nasopharyngeal carcinoma patients [@bb0135]. Lien et al reported that preoperative low serum albumin level was an independent factor correlated with prognosis and that postoperative adjuvant therapy should be given to all GC patients with hypoalbuminemia preoperatively [@bb0140]. Additionally, several composite scoring systems, including the Nutritional Risk Index, Nutritional Risk Score, and Geriatric Assessment, also failed to gain widespread consensus for nutrition evaluation in gastrointestinal malignancies [@bb0045], [@bb0145]. Thus, up to now, no standardized method exists to identify patients at a high nutritional risk preoperatively.

In recent years, a new nutritional-based score, which includes objective and easily measurable criteria, has been increasingly getting attention. ND, as measured by BMI, serum albumin, and preoperative weight loss, has been validated as a strong predictor of clinical outcome in urologic malignancies. One group found that ND was associated with increased 90-day mortality and poor OS in patients undergoing radical cystectomy for bladder cancer [@bb0070]. Another study reported that ND was a significant predictor of overall mortality in patients undergoing nephrectomy for renal cell carcinoma, independent of key clinicopathological factors [@bb0075]. In fact, our conclusions were in line with the studies.

In the current study, we found that preoperative ND was independently predictive of poor OS after curative resection for GC, especially in TNM stage II and III GC. In subgroup analyses, its prognostic significance was still maintained when stratified by age, sex, anemia, and adjuvant chemotherapy. Furthermore, we found that preoperative ND was associated with larger tumor size and higher TNM stage. The observation was supported by previous studies which indicated that poor nutritional status was significantly parallel to tumor progression [@bb0150]. Tokunaga et al recently demonstrated in a cohort of 556 patients with colorectal cancer undergoing surgery that poor nutritional status was correlated with tumors invading muscular or deeper layers, distant metastasis, tumor recurrence, and poor survival [@bb0155].

Of note, ND was still associated with OS in patients with BMI ≥18.5 kg/m^2^, preoperative weight loss \<5% of body weight, or serum albumin ≥35 g/l, respectively. These data suggest, therefore, that ND may identify more patients at high risk of recurrence or mortality than the individual index. Obviously, ND, which includes all three variables, was a more comprehensive and superior predictor to evaluate nutritional status in GC. Furthermore, in stage-stratified analysis, ND may have merit as a gauge of prognosis in patients with GC at stage II and III. We speculated, in the context of stage I GC, that nutritional status did not exert potent prognostic value. Given that studies of Gregg and Morgan did not perform subgroup analysis to support our conclusion, it is worthy of being further verified in future studies [@bb0070], [@bb0075].

In clinical practice, ND patients may need closer follow-up and more aggressive adjuvant therapy. In addition, patients with ND may benefit from nutritional support [@bb0160], [@bb0165]. At present, although many studies have reported the promising results of targeted nutritional intervention in GC, no standardized method or strategy exists to select appropriate patients [@bb0170], [@bb0175]. Therefore, whether ND may aid in the selection of patients with stage II to III GC likely to benefit from nutritional intervention would be of considerable interest.

A potential limitation of the present study is that it was a retrospective single-center study. However, our study is based on a large and representative sample, which provides a valid base to evaluate the prognostic significance of nutritional status. In addition, postoperative treatment heterogeneity was inevitable because of the retrospective design, which might have confounded the results. Finally, we lack complete information on postoperative complications in our medical records. As a result, future studies are needed to further explore the relationship between ND and postoperative complications.

Conclusions {#s0055}
===========

Our study showed that ND was a valuable independent predictor of outcome in patients undergoing curative resection for GC, especially in stage II to III GC. With our results in mind, we encourage prospective randomized multicenter trials determining the clinical utility of nutritional intervention in GC patients with ND.
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###### 

General Characteristics of 1026 GC Patients

                             No. of Patients (%)
  -------------------------- ---------------------
  Age (y)                    
   \< 60                     544 (53.0%)
   ≥ 60                      482 (47.0%)
  Sex                        
   Female                    326 (31.8%)
   Male                      700 (68.2%)
  Tumor size (cm)            
   \<5                       583 (56.8%)
   ≥5                        443 (43.2%)
  Tumor location             
   Upper third               411 (40.1%)
   Middle third              202 (19.7%)
   Lower third               413 (40.3%)
  Histological grade         
   Well differentiated       175 (17.1%)
   Poorly differentiated     851 (82.9%)
  Anemia                     
   No                        737 (71.8%)
   Yes                       289 (28.2%)
  BMI (kg/m^2^)              
   \<18.5                    401 (39.1%)
   ≥18.5 to \<25.0           351 (34.2%)
   ≥25.0                     274 (26.7%)
  Serum albumin (g/l)        
   ≥35                       941 (91.7%)
   \<35                      85 (8.3%)
  Preoperative weight loss   
   \<5%                      694 (67.6%)
   ≥5% to ≤10%               221 (21.5%)
   \>10%                     111 (10.8%)
  Nutrition status           
   NR                        441 (43.0%)
   ND                        585 (57.0%)
  CEA                        
   Normal                    742 (77.6%)
   Elevated                  214 (22.4%)
  TNM stage                  
   I                         177 (17.3%)
   II                        257 (25.0%)
   III                       592 (57.7%)
  Adjuvant chemotherapy      
   No                        393 (38.3%)
   Yes                       633 (61.7%)

###### 

Univariate and Multivariate Analyses of OS in 1026 Patients Undergoing Curative Resection for GC

                             Univariate Analysis     Multivariate Analysis                          
  -------------------------- ----------------------- ----------------------- ---------------------- --------
  Age (y)                                            \<.001                                         \<.001
   \<60                      1.00                                            1.00                   
   ≥60                       1.462 (1.200-1.781)                             1.556 (1.259-1.923)    
  Sex                                                .188                                           
   Female                    1.00                                                                   
   Male                      0.870 (0.707-1.071)                                                    
  Tumor size (cm)                                    \<.001                                         .705
   \<5                       1.00                                            1.00                   
   ≥5                        1.915 (1.571-2.335)                             1.044 (0.837-1.302)    
  Tumor location                                     \<.001                                         .003
   Upper third               1.00                                            1.00                   
   Middle third              0.613 (0.467-0.804)     \<.001                  0.769 (0.578-1.025)    .073
   Lower third               0.481 (0.384-0.602)     \<.001                  0.665 (0.522-0.847)    .001
  Histological grade                                 .014                                           .015
   Well differentiated       1.00                                            1.00                   
   Poorly differentiated     1.441 (1.077-1.929)                             1.487 (1.081-2.046)    
  Anemia                                             .006                                           .702
   No                        1.00                                            1.00                   
   Yes                       1.349 (1.092-1.667)                             1.045 (0.837-1.311)    
  BMI (kg/m^2^)                                      \<.001                                         
   \<18.5                    1.00                                                                   
   ≥18.5 to \<25.0           0.817 (0.654-1.022)     .077                                           
   ≥25.0                     0.593 (0.457-0.768)     \<.001                                         
  Serum albumin (g/l)                                \<.001                                         
   \<35                      1.00                                                                   
   ≥35                       2.362 (1.767-3.156)                                                    
  Preoperative weight loss                           \<.001                                         
   \<5%                      1.00                                                                   
   ≥5% to ≤10%               2.156 (1.722-2.698)     \<.001                                         
   \>10%                     2.184 (1.635-2.918)     \<.001                                         
  Nutrition status                                   \<.001                                         \<.001
   NR                        1.00                                            1.00                   
   ND                        2.326 (1.876-2.885)                             1.954 (1.552-2.460)    
  CEA                                                \<.001                                         .364
   Normal                    1.00                                            1.00                   
   Elevated                  1.665 (1.327-2.090)                             1.114 (0.883-1.405)    
  TNM stage                                          \<.001                                         \<.001
   I                         1.00                                            1.00                   
   II                        2.970 (1.602-5.507)     \<.001                  2.429 (1.265-4.662)    .008
   III                       12.573 (7.219-21.896)   \<.001                  9.986 (5.537-18.008)   \<.001
  Adjuvant chemotherapy                              .799                                           
   No                        1.00                                                                   
   Yes                       0.974 (0.794-1.194)                                                    

###### 

The Relationships between Nutrition Status and Clinicopathological Characteristics

                           NR    ND    *P* Value
  ------------------------ ----- ----- -----------
  Age (y)                              .030
   \<60                    251   293   
   ≥60                     190   292   
  Sex                                  \<.001
   Female                  94    232   
   Male                    347   353   
  Tumor size (cm)                      \<.001
   \<5                     294   289   
   ≥5                      147   296   
  Tumor location                       .103
   Upper third             167   244   
   Middle third            80    122   
   Lower third             194   219   
  Histological grade                   .332
   Well differentiated     81    94    
   Poorly differentiated   360   491   
  Anemia                               \<.001
   No                      355   382   
   Yes                     86    203   
  CEA                                  .006
   Normal                  346   396   
   Elevated                77    137   
  TNM stage                            \<.001
   I                       104   73    
   II                      119   138   
   III                     218   374   
  Adjuvant chemotherapy                .690
   No                      172   221   
   Yes                     269   364   

[^1]: Xuechao Liu and Pengfei Xu contributed equally to this work.
